Clinical Trial Update: Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SHR-1210 (anti-PD-1) plus nimotuzumab for advanced esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN